JOURNAL OF CLINICAL LABORATORY ANALYSIS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2022-03-05 sunrise19890224

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：诊断;基因多态性;临床检验
经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi

85 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2021-10-04 heyuan2396

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0
偏重的研究方向：甲状腺癌
经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。

47 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2022-11-30 148999f2m69暂无昵称来自陕西省

偏重的研究方向：生物标记物检测
经验分享：各位大佬，这个杂志Under Review和Under review有区别吗

10 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2023-03-03 ms6000000883078349 来自江苏省

请问大家submitted多久 under reviewer？

30 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2023-01-30 ms7000000968129421 来自云南省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：投稿半个月直接被拒，理由也没有

38 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2020-10-20 121bf907m43暂无昵称

审稿速度:1.0 | 投稿命中率:75.0
经验分享：非常高效的杂志
9.18 submitted
10.04 minor revision
10.10 a revision has been submitted
10.17 accept
修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！

167 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2022-12-06 148999f2m69暂无昵称来自陕西省

审稿速度:1.0
经验分享：请问修回后有Under Review的状态吗

29 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2022-03-18 ms4000000222994216

审稿速度:6.0 | 投稿命中率:75.0
经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤
2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）

44 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2022-11-07 ms5000001226862916

请问这个杂志接受纯生信文章嘛

34 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1199707, encodeId=44561199e070f, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：诊断;基因多态性;临床检验 经验分享：在这本期刊中过四篇，有幸成为期刊的reviewer，对于此杂志投稿各个阶段状态和杂志社喜好的文章类型都非常的了解。有需要了解这本杂志任何情况的都可以问我。v：Langzhongxiangxiuxi, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=339e1959506, createdName=sunrise19890224, createdTime=Sat Mar 05 19:07:52 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057455, encodeId=f099105e45554, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2200.0 偏重的研究方向：甲状腺癌 经验分享：审稿快，审稿意见中肯，审稿人和编辑都很nice。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2aee1454707, createdName=heyuan2396, createdTime=Mon Oct 04 12:15:55 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2103451, encodeId=0910210345114, content=偏重的研究方向：生物标记物检测 经验分享：各位大佬，这个杂志Under Review和Under review有区别吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Wed Nov 30 09:01:26 CST 2022, time=2022-11-30, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2117326, encodeId=8fda211e326d8, content=请问大家submitted多久 under reviewer？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deec6495378, createdName=ms6000000883078349, createdTime=Fri Mar 03 11:05:25 CST 2023, time=2023-03-03, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2112082, encodeId=4fae2112082de, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：投稿半个月直接被拒，理由也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2428272697, createdName=ms7000000968129421, createdTime=Mon Jan 30 09:45:03 CST 2023, time=2023-01-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=893359, encodeId=36f1893359d3, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：非常高效的杂志 9.18 submitted 10.04 minor revision 10.10 a revision has been submitted 10.17 accept 修回后等的过程很煎熬，虽然不过一周时间，还好幸运赶上秋季申请学位的末班车，很感谢这个杂志了！祝小伙伴们都顺利！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/448954046c7d4151b36a9b11b3019d44/ee9973611e2b4b68addf0498cbc7e0d6.jpg, createdBy=3d592278970, createdName=121bf907m43暂无昵称, createdTime=Tue Oct 20 19:17:19 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104617, encodeId=c787210461e3b, content=审稿速度:1.0 经验分享：请问修回后有Under Review的状态吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a8a5315883, createdName=148999f2m69暂无昵称, createdTime=Tue Dec 06 19:46:02 CST 2022, time=2022-12-06, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1203892, encodeId=22f0120389258, content=审稿速度:6.0 | 投稿命中率:75.0 经验分享：期刊效率很高，审稿人和编辑很友好。生信肿瘤 2021.12.09（提交）--12.21（大修：10条意见补了实验验证）--2022.02.24（修回）--03.06（大修）--03.08（修回）-03.10（大修）--03.15（修回）--03.17（小修）--17（修回）--2022.03.18（接收）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecfc5706039, createdName=ms4000000222994216, createdTime=Fri Mar 18 21:07:18 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098930, encodeId=960220989306b, content=请问这个杂志接受纯生信文章嘛, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd535555461, createdName=ms5000001226862916, createdTime=Mon Nov 07 10:11:27 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217342, encodeId=3ca5121e34214, content=偏重的研究方向：诊断 经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47a46579484, createdName=ms7000001844459526, createdTime=Fri May 06 13:06:49 CST 2022, time=2022-05-06, status=1, ipAttribution=)]

2022-05-06 ms7000001844459526

偏重的研究方向：诊断
经验分享：文章5.1Accept，Complete Final File Updates，接下来就等待期刊发邮件需不需要 final versions of files和版权协议了吗？

38 13

展开13条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务